person · Reporting owner

GOUDIS RICHARD

Disclosed activity across 2 companies

Tapewire entity: 115397
SEC CIK: 0001311175

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
HERBALIFE LTD.HLF · Entity 4842	Chief Executive Officer	September 17, 2018	September 18, 2018
TUPPERWARE BRANDS CORPTUP · Entity 90566	Director · Executive Vice Chair	February 27, 2023	March 20, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HERBALIFE LTD.

Report date September 17, 2018 · Filed September 18, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	676,802	Reported balance After 2018-09-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-09-17 · Exercise / conversion · Acquired 240,000 · Balance 676,802 F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F2: On May 14, 2018, the common stock of Herbalife Nutrition Ltd. split 2-for-1, resulting in the reporting person's acquisition of 218,401 additional shares of common stock.
Common StockSEC Table I · non-derivative	Direct	631,804	Reported balance After 2018-09-17 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2018-09-17 · Disposition to issuer · Disposed 44,998 · Balance 631,804 F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	529,720	Reported balance After 2018-09-17 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2018-09-17 · Tax withholding · Disposed 102,084 · Balance 529,720 F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	635,906	Reported balance After 2018-09-17 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2018-09-17 · Exercise / conversion · Acquired 106,186 · Balance 635,906 F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	613,805	Reported balance After 2018-09-17 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2018-09-17 · Disposition to issuer · Disposed 22,101 · Balance 613,805 F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	569,786	Reported balance After 2018-09-17 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2018-09-17 · Tax withholding · Disposed 44,019 · Balance 569,786 F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	685,804	Reported balance After 2018-09-17 transaction · row 7 Account or security details depend on footnotes; rows are not merged. 1 source row Row 7 · 2018-09-17 · Exercise / conversion · Acquired 116,018 · Balance 685,804 F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	629,710	Reported balance After 2018-09-17 transaction · row 8 Account or security details depend on footnotes; rows are not merged. 1 source row Row 8 · 2018-09-17 · Disposition to issuer · Disposed 56,094 · Balance 629,710 F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	598,339	Reported balance After 2018-09-17 transaction · row 9 Account or security details depend on footnotes; rows are not merged. 1 source row Row 9 · 2018-09-17 · Tax withholding · Disposed 31,371 · Balance 598,339 F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	835,191	Reported balance After 2018-09-17 transaction · row 10 Account or security details depend on footnotes; rows are not merged. 1 source row Row 10 · 2018-09-17 · Exercise / conversion · Acquired 236,852 · Balance 835,191 F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	738,941	Reported balance After 2018-09-17 transaction · row 11 Account or security details depend on footnotes; rows are not merged. 1 source row Row 11 · 2018-09-17 · Disposition to issuer · Disposed 96,250 · Balance 738,941 F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	665,335	Reported balance After 2018-09-17 transaction · row 12 Account or security details depend on footnotes; rows are not merged. 1 source row Row 12 · 2018-09-17 · Tax withholding · Disposed 73,606 · Balance 665,335 F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	774,657	Reported balance After 2018-09-17 transaction · row 13 Account or security details depend on footnotes; rows are not merged. 1 source row Row 13 · 2018-09-17 · Exercise / conversion · Acquired 109,322 · Balance 774,657 F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	695,723	Reported balance After 2018-09-17 transaction · row 14 Account or security details depend on footnotes; rows are not merged. 1 source row Row 14 · 2018-09-17 · Disposition to issuer · Disposed 78,934 · Balance 695,723 F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	679,812	Reported balance After 2018-09-17 transaction · row 15 Account or security details depend on footnotes; rows are not merged. 1 source row Row 15 · 2018-09-17 · Tax withholding · Disposed 15,911 · Balance 679,812 F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	846,616	Reported balance After 2018-09-17 transaction · row 16 Account or security details depend on footnotes; rows are not merged. 1 source row Row 16 · 2018-09-17 · Exercise / conversion · Acquired 166,804 · Balance 846,616 F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	755,842	Reported balance After 2018-09-17 transaction · row 17 Account or security details depend on footnotes; rows are not merged. 1 source row Row 17 · 2018-09-17 · Disposition to issuer · Disposed 90,774 · Balance 755,842 F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	716,038	Reported balance After 2018-09-17 transaction · row 18 Account or security details depend on footnotes; rows are not merged. 1 source row Row 18 · 2018-09-17 · Tax withholding · Disposed 39,804 · Balance 716,038 F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	960,736	Reported balance After 2018-09-17 transaction · row 19 Account or security details depend on footnotes; rows are not merged. 1 source row Row 19 · 2018-09-17 · Exercise / conversion · Acquired 244,698 · Balance 960,736 F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	893,154	Reported balance After 2018-09-17 transaction · row 20 Account or security details depend on footnotes; rows are not merged. 1 source row Row 20 · 2018-09-17 · Disposition to issuer · Disposed 67,582 · Balance 893,154 F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	800,431	Reported balance After 2018-09-17 transaction · row 21 Account or security details depend on footnotes; rows are not merged. 1 source row Row 21 · 2018-09-17 · Tax withholding · Disposed 92,723 · Balance 800,431 F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	966,931	Reported balance After 2018-09-17 transaction · row 22 Account or security details depend on footnotes; rows are not merged. 1 source row Row 22 · 2018-09-17 · Exercise / conversion · Acquired 166,500 · Balance 966,931 F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	894,722	Reported balance After 2018-09-17 transaction · row 23 Account or security details depend on footnotes; rows are not merged. 1 source row Row 23 · 2018-09-17 · Disposition to issuer · Disposed 72,209 · Balance 894,722 F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	845,358	Reported balance After 2018-09-17 transaction · row 24 Account or security details depend on footnotes; rows are not merged. 1 source row Row 24 · 2018-09-17 · Tax withholding · Disposed 49,364 · Balance 845,358 F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	893,890	Reported balance After 2018-09-17 transaction · row 25 Account or security details depend on footnotes; rows are not merged. 1 source row Row 25 · 2018-09-17 · Exercise / conversion · Acquired 48,532 · Balance 893,890 F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	866,364	Reported balance After 2018-09-17 transaction · row 26 Account or security details depend on footnotes; rows are not merged. 1 source row Row 26 · 2018-09-17 · Disposition to issuer · Disposed 27,526 · Balance 866,364 F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	855,366	Reported balance After 2018-09-17 transaction · row 27 Account or security details depend on footnotes; rows are not merged. 1 source row Row 27 · 2018-09-17 · Tax withholding · Disposed 10,998 · Balance 855,366 F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	880,874	Reported balance After 2018-09-17 transaction · row 28 Account or security details depend on footnotes; rows are not merged. 1 source row Row 28 · 2018-09-17 · Exercise / conversion · Acquired 25,508 · Balance 880,874 F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	867,638	Reported balance After 2018-09-17 transaction · row 29 Account or security details depend on footnotes; rows are not merged. 1 source row Row 29 · 2018-09-17 · Disposition to issuer · Disposed 13,236 · Balance 867,638 F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Common StockSEC Table I · non-derivative	Direct	861,213	Reported balance After 2018-09-17 transaction · row 30 Account or security details depend on footnotes; rows are not merged. 1 source row Row 30 · 2018-09-17 · Tax withholding · Disposed 6,425 · Balance 861,213 F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2020-01-04	Direct	0	Reported balance After 2018-09-17 transaction · row 31 Instrument identity requires review; Table II rows are not merged. 1 source row Row 31 · 2018-09-17 · Exercise / conversion · Disposed 240,000 · Balance 0 F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F12: These SARS were previously reported as covering 120,000 shares at an exercise price of $20.67 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $11.47 · Expires 2020-05-07	Direct	0	Reported balance After 2018-09-17 transaction · row 32 Instrument identity requires review; Table II rows are not merged. 1 source row Row 32 · 2018-09-17 · Exercise / conversion · Disposed 106,186 · Balance 0 F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F13: These SARS were previously reported as covering 66,366 shares at an exercise price of $22.94 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $26.65 · Expires 2021-05-18	Direct	0	Reported balance After 2018-09-17 transaction · row 33 Instrument identity requires review; Table II rows are not merged. 1 source row Row 33 · 2018-09-17 · Exercise / conversion · Disposed 116,018 · Balance 0 F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F14: These SARS were previously reported as covering 58,009 shares at an exercise price of $53.29 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $22.40 · Expires 2022-05-31	Direct	0	Reported balance After 2018-09-17 transaction · row 34 Instrument identity requires review; Table II rows are not merged. 1 source row Row 34 · 2018-09-17 · Exercise / conversion · Disposed 236,852 · Balance 0 F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F15: These SARS were previously reported as covering 118,426 shares at an exercise price of $44.79 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $39.79 · Expires 2023-12-19	Direct	0	Reported balance After 2018-09-17 transaction · row 35 Instrument identity requires review; Table II rows are not merged. 1 source row Row 35 · 2018-09-17 · Exercise / conversion · Disposed 109,322 · Balance 0 F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F16: These SARS were previously reported as covering 54,661 shares at an exercise price of $79.58 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $29.99 · Expires 2024-04-30	Direct	0	Reported balance After 2018-09-17 transaction · row 36 Instrument identity requires review; Table II rows are not merged. 1 source row Row 36 · 2018-09-17 · Exercise / conversion · Disposed 166,804 · Balance 0 F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F17: These SARS were previously reported as covering 83,402 shares at an exercise price of $59.98 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $15.22 · Expires 2025-03-02	Direct	0	Reported balance After 2018-09-17 transaction · row 37 Instrument identity requires review; Table II rows are not merged. 1 source row Row 37 · 2018-09-17 · Exercise / conversion · Disposed 244,698 · Balance 0 F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F18: These SARS were previously reported as covering 122,349 shares at an exercise price of $30.44 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $23.90 · Expires 2025-05-07	Direct	0	Reported balance After 2018-09-17 transaction · row 38 Instrument identity requires review; Table II rows are not merged. 1 source row Row 38 · 2018-09-17 · Exercise / conversion · Disposed 166,500 · Balance 0 F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F19: These SARS were previously reported as covering 83,250 shares at an exercise price of $47.80 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2026-05-09	Direct	72,798	Reported balance After 2018-09-17 transaction · row 39 Instrument identity requires review; Table II rows are not merged. 1 source row Row 39 · 2018-09-17 · Exercise / conversion · Disposed 48,532 · Balance 72,798 F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F20: On May 9, 2016, the reporting person was granted 60,665 SARs. These SARs vested 20% each on May 9, 2017 and May 9, 2018, and 60% will vest on May 9, 2019. F21: These SARS were previously reported as covering 60,665 shares at an exercise price of $62.51 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $28.60 · Expires 2027-02-27	Direct	102,034	Reported balance After 2018-09-17 transaction · row 40 Instrument identity requires review; Table II rows are not merged. 1 source row Row 40 · 2018-09-17 · Exercise / conversion · Disposed 25,508 · Balance 102,034 F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F22: On February 27, 2017, the reporting person was granted 63,771 SARs. These SARs vested 20% on February 27, 2018 and 20% will vest on February 27, 2019 and 60% will vest on February 27, 2020. F23: These SARS were previously reported as covering 63,771 shares at an exercise price of $57.19 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F2: On May 14, 2018, the common stock of Herbalife Nutrition Ltd. split 2-for-1, resulting in the reporting person's acquisition of 218,401 additional shares of common stock.

F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.

F12: These SARS were previously reported as covering 120,000 shares at an exercise price of $20.67 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F13: These SARS were previously reported as covering 66,366 shares at an exercise price of $22.94 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F14: These SARS were previously reported as covering 58,009 shares at an exercise price of $53.29 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F15: These SARS were previously reported as covering 118,426 shares at an exercise price of $44.79 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F16: These SARS were previously reported as covering 54,661 shares at an exercise price of $79.58 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F17: These SARS were previously reported as covering 83,402 shares at an exercise price of $59.98 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F18: These SARS were previously reported as covering 122,349 shares at an exercise price of $30.44 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F19: These SARS were previously reported as covering 83,250 shares at an exercise price of $47.80 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F20: On May 9, 2016, the reporting person was granted 60,665 SARs. These SARs vested 20% each on May 9, 2017 and May 9, 2018, and 60% will vest on May 9, 2019.

F21: These SARS were previously reported as covering 60,665 shares at an exercise price of $62.51 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

F22: On February 27, 2017, the reporting person was granted 63,771 SARs. These SARs vested 20% on February 27, 2018 and 20% will vest on February 27, 2019 and 60% will vest on February 27, 2020.

F23: These SARS were previously reported as covering 63,771 shares at an exercise price of $57.19 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.

TUPPERWARE BRANDS CORP

Report date February 27, 2023 · Filed March 20, 2023 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	52,275	Reported balance After 2023-02-27 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2023-02-27 · Tax withholding · Disposed 1,813 · Balance 52,275 F1: Shares were withheld by the Issuer upon the vesting of the reporting person's February 25, 2022 restricted stock units award to cover the resulting tax liability. On February 25, 2022, the reporting person was granted 6,113 restricted stock units with a vesting schedule of 100% on February 25, 2023, the anniversary of the grant. F2: The Form 4 filed on February 28, 2023 is hereby amended to correct the vesting schedule of the shares granted to the Reporting Person.
Common StockSEC Table I · non-derivative	IndirectGoudis Family Revocable Trust	424,500	Reported balance Holding disclosure · report date 2023-02-27 · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · Balance 424,500

Filing footnotes · ownership attribution and instrument terms

F1: Shares were withheld by the Issuer upon the vesting of the reporting person's February 25, 2022 restricted stock units award to cover the resulting tax liability. On February 25, 2022, the reporting person was granted 6,113 restricted stock units with a vesting schedule of 100% on February 25, 2023, the anniversary of the grant.

F2: The Form 4 filed on February 28, 2023 is hereby amended to correct the vesting schedule of the shares granted to the Reporting Person.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 12, 2023 Filed Mar 13, 2023 17:03 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	GrantCommon Stock	533,384	$2.95	$1,573,482.80	Disclosure SEC source: 0001127602-23-009897 · form4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,659 F1 · shares: Represents shares awarded to reporting person in connection with the vesting of performance-based PSUs initially awarded on March 12, 2020. 266,616 shares were surrendered to cover the resulting tax liability. Read SEC document
February 27, 2023 Filed Feb 28, 2023 16:38 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	Tax withholdingCommon Stock	1,813	$3.81	$6,907.53	Disclosure SEC source: 0001127602-23-007544 · form4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,275 F1 · kind: Shares were withheld by the Issuer upon the vesting of 1/3 of the reporting person's February 25, 2022 restricted stock units award to cover the resulting tax liability. On February 25, 2022, the reporting person was granted 6,113 restricted stock units with a vesting schedule of 3 equal annual installments beginning on February 25, 2023, the first anniversary of the grant. Read SEC document
February 27, 2023 Filed Mar 20, 2023 17:18 UTC Amendment	TUPPERWARE BRANDS CORP TUP · Entity 90566	Tax withholdingCommon Stock	1,813	$3.81	$6,907.53	Disclosure SEC source: 0001127602-23-010878 · form4a.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,275 F1 · kind: Shares were withheld by the Issuer upon the vesting of the reporting person's February 25, 2022 restricted stock units award to cover the resulting tax liability. On February 25, 2022, the reporting person was granted 6,113 restricted stock units with a vesting schedule of 100% on February 25, 2023, the anniversary of the grant. F2 · kind: The Form 4 filed on February 28, 2023 is hereby amended to correct the vesting schedule of the shares granted to the Reporting Person. Read SEC document
November 04, 2022 Filed Nov 7, 2022 08:26 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	PurchaseCommon Stock	254,500	$3.93	$1,000,134.10	Disclosure SEC source: 0001127602-22-024987 · form4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Indirect · Goudis Family Revocable Trust Disclosed balance after: 424,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.87 to $3.98, inclusive. The reporting person undertakes to provide to Tupperware Brands Corporation, any security holder of Tupperware Brands Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document
June 10, 2022 Filed Jun 14, 2022 17:11 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	PurchaseCommon Stock	170,000	$6.07	$1,031,900.00	Disclosure SEC source: 0001127602-22-017477 · form4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Indirect · Goudis Family Revocable Trust Disclosed balance after: 170,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.95 to $6.24, inclusive. The reporting person undertakes to provide to Tupperware Brands Corporation, any security holder of Tupperware Brands Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document
February 25, 2022 Filed Mar 1, 2022 10:05 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	GrantCommon Stock	6,113	$0.00	$0.00	Disclosure SEC source: 0001127602-22-007205 · form4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,088 F1 · date: Restricted Stock Unit award vests in its entirety on February 25, 2023. Read SEC document
March 12, 2021 Filed Mar 15, 2021 09:48 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	PurchaseCommon Stock	20,475	$24.36	$498,811.95	Disclosure SEC source: 0001127602-21-010506 · form4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,975 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.12 to $24.68, inclusive. The reporting person undertakes to provide to Tupperware Brands Corporation, any security holder of Tupperware Brands Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document
November 10, 2020 Filed Nov 10, 2020 17:57 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	PurchaseCommon Stock	27,500	$28.64	$787,600.00	Disclosure SEC source: 0001127602-20-028668 · form4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.60 to $28.77, inclusive. The reporting person undertakes to provide to Tupperware Brands Corporation, any security holder of Tupperware Brands Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document
March 12, 2020 Filed Mar 16, 2020 13:30 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	GrantPerformance Units · Derivative	800,000	$0.00	$0.00	Disclosure SEC source: 0001127602-20-010733 · form4.xml · derivative · entry 2 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2025-03-12 F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Issuer's common stock, upon satisfaction of vesting conditions based on the closing price of the Issuer's common stock as described in the applicable award agreement, filed with the Securities and Exchange Commission as Exhibit 10.2 to Form S-8 on March 12, 2020. F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Issuer's common stock, upon satisfaction of vesting conditions based on the closing price of the Issuer's common stock as described in the applicable award agreement, filed with the Securities and Exchange Commission as Exhibit 10.2 to Form S-8 on March 12, 2020. Read SEC document
March 12, 2020 Filed Mar 16, 2020 13:30 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	GrantStock Option · Derivative	1,000,000	$0.00 Strike: $2.61	$0.00	Disclosure SEC source: 0001127602-20-010733 · form4.xml · derivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Director · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-03-11 F1 · derivative.exercise_price: Exercise price represents 115% of the Issuer's common stock closing price on March 12, 2020 ($2.27 per share). Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	25,508	$0.00 Strike: $28.60	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 40 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,034 Underlying: Common Stock · 25,508 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · kind: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F22 · derivative.exercise_date: On February 27, 2017, the reporting person was granted 63,771 SARs. These SARs vested 20% on February 27, 2018 and 20% will vest on February 27, 2019 and 60% will vest on February 27, 2020. F23 · derivative.underlying_shares: These SARS were previously reported as covering 63,771 shares at an exercise price of $57.19 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	48,532	$0.00 Strike: $31.26	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 39 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,798 Underlying: Common Stock · 48,532 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · kind: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F20 · derivative.exercise_date: On May 9, 2016, the reporting person was granted 60,665 SARs. These SARs vested 20% each on May 9, 2017 and May 9, 2018, and 60% will vest on May 9, 2019. F21 · derivative.underlying_shares: These SARS were previously reported as covering 60,665 shares at an exercise price of $62.51 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	166,500	$0.00 Strike: $23.90	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 38 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,500 shares Expires 2025-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · kind: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F19 · derivative.underlying_shares: These SARS were previously reported as covering 83,250 shares at an exercise price of $47.80 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	244,698	$0.00 Strike: $15.22	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 37 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 244,698 shares Expires 2025-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F18 · derivative.underlying_shares: These SARS were previously reported as covering 122,349 shares at an exercise price of $30.44 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	166,804	$0.00 Strike: $29.99	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 36 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,804 shares Expires 2024-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F17 · derivative.underlying_shares: These SARS were previously reported as covering 83,402 shares at an exercise price of $59.98 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	109,322	$0.00 Strike: $39.79	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 35 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,322 shares Expires 2023-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F16 · derivative.underlying_shares: These SARS were previously reported as covering 54,661 shares at an exercise price of $79.58 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	236,852	$0.00 Strike: $22.40	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 34 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 236,852 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F15 · derivative.underlying_shares: These SARS were previously reported as covering 118,426 shares at an exercise price of $44.79 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	116,018	$0.00 Strike: $26.65	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 33 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 116,018 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F14 · derivative.underlying_shares: These SARS were previously reported as covering 58,009 shares at an exercise price of $53.29 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	106,186	$0.00 Strike: $11.47	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 32 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,186 shares Expires 2020-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F13 · derivative.underlying_shares: These SARS were previously reported as covering 66,366 shares at an exercise price of $22.94 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionStock Appreciation Rights · Derivative	240,000	$0.00 Strike: $10.33	$0.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 31 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires 2020-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F12 · derivative.underlying_shares: These SARS were previously reported as covering 120,000 shares at an exercise price of $20.67 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	6,425	$55.11	$354,081.75	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 30 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 861,213 F11 · kind: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	13,236	$55.11	$729,435.96	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 29 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,638 F11 · kind: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	25,508	$28.60	$729,528.80	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 28 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · kind: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	10,998	$55.11	$606,099.78	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 27 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,366 F10 · kind: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	27,526	$55.11	$1,516,957.86	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 26 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,364 F10 · kind: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	48,532	$31.26	$1,517,110.32	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 25 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · kind: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	49,364	$55.11	$2,720,450.04	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 24 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,358 F9 · kind: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	72,209	$55.11	$3,979,437.99	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 23 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,722 F9 · kind: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	166,500	$23.90	$3,979,350.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 22 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · kind: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	92,723	$55.11	$5,109,964.53	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 21 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,431 F8 · kind: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	67,582	$55.11	$3,724,444.02	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 20 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,154 F8 · kind: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	244,698	$15.22	$3,724,303.56	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 19 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	39,804	$55.11	$2,193,598.44	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 18 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,038 F7 · kind: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	90,774	$55.11	$5,002,555.14	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 17 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,842 F7 · kind: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	166,804	$29.99	$5,002,451.96	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 16 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	15,911	$55.11	$876,855.21	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 15 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679,812 F6 · kind: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	78,934	$55.11	$4,350,052.74	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 14 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,723 F6 · kind: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	109,322	$39.79	$4,349,922.38	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 13 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	73,606	$55.11	$4,056,426.66	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 12 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,335 F5 · kind: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	96,250	$55.11	$5,304,337.50	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 11 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,941 F5 · kind: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	236,852	$22.40	$5,305,484.80	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 10 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	31,371	$55.11	$1,728,855.81	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 9 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,339 F4 · kind: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	56,094	$55.11	$3,091,340.34	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 8 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,710 F4 · kind: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	116,018	$26.65	$3,091,879.70	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 7 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	44,019	$55.11	$2,425,887.09	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 6 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,786 F3 · kind: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	22,101	$55.11	$1,217,986.11	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 5 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,805 F3 · kind: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	106,186	$11.47	$1,217,953.42	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 4 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Tax withholdingCommon Stock	102,084	$55.11	$5,625,849.24	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 3 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,720 F1 · kind: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Disposition to issuerCommon Stock	44,998	$55.11	$2,479,839.78	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 2 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,804 F1 · kind: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document
September 17, 2018 Filed Sep 18, 2018 20:36 UTC	HERBALIFE LTD. HLF · Entity 4842	Exercise / conversionCommon Stock	240,000	$10.33	$2,479,200.00	Disclosure SEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F2 · balance_after: On May 14, 2018, the common stock of Herbalife Nutrition Ltd. split 2-for-1, resulting in the reporting person's acquisition of 218,401 additional shares of common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.